Literature DB >> 10534161

Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant?

E Lloret1, M Mollejo, M S Mateo, R Villuendas, P Algara, P Martínez, M A Piris.   

Abstract

Splenic marginal zone lymphoma (SMZL) is a recently described and distinctive type of splenic lymphoma and is characterized by an indolent clinical course. By analyzing a large series of SMZL cases, we recognized the existence of a subset of 6 cases characterized by an aggressive clinical course that led to death caused by the tumor in 5 of 6 cases, whereas the remaining patient showed signs of tumor progression. The morphological, immunohistological, and molecular study of these cases has allowed us to detect precise distinctive features of this SMZL variant. The cases included here were characterized by massive splenomegaly and a morphological picture showing a micronodular pattern of splenic involvement with follicle replacement, biphasic cytology, and marginal zone differentiation. Unlike classical SMZL cases, a conspicuous component of larger lymphocytes was distributed in the marginal zone ring, occasionally overrunning it, with isolated presence of the same cells within the central small cell component and also in the red pulp. The bone marrow and peripheral lymph nodes showed similar histological findings to those described for SMZL in these locations. The genetic and molecular study of these cases showed no alterations specific to other lymphoma types, such as t14;18 and t11;14. Instead of this, it showed 7q loss in 3 of 5 cases, p53 inactivation in 2 of 6 cases, cyclinD1 overexpression in 2 of 6 cases, and the presence of translocations involving the 1q32 region in 2 of 4 cases. The recognition of this aggressive variant, besides offering a prognostic indication, could lead to a more suitable form of clinical management of these patients. Further molecular studies would clarify the role of the different genetic alterations found.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534161     DOI: 10.1016/s0046-8177(99)90031-x

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

Review 1.  Nodal aggressive B-cell lymphomas: a diagnostic approach.

Authors:  Sonam Prakash; Steven H Swerdlow
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

Review 2.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

Review 3.  Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis.

Authors:  Marcus Kremer; Leticia Quintanilla-Martínez; Jörg Nährig; Christoph von Schilling; Falko Fend
Journal:  Virchows Arch       Date:  2005-10-18       Impact factor: 4.064

4.  Primary prostatic lymphoma with components of both diffuse large B-cell lymphoma (DLBCL) and MALT lymphoma.

Authors:  G Petrakis; T Koletsa; V Karavasilis; G Rallis; M Bobos; G Karkavelas; I Kostopoulos
Journal:  Hippokratia       Date:  2012-01       Impact factor: 0.471

5.  Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.

Authors:  Thomas Menter; Alexandar Tzankov; Visar Vela; Darius Juskevicius; Stefan Dirnhofer
Journal:  Virchows Arch       Date:  2021-09-08       Impact factor: 4.064

Review 6.  CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.

Authors:  John J Schmieg; Jeannie M Muir; Nadine S Aguilera; Aaron Auerbach
Journal:  Curr Oncol       Date:  2021-12-04       Impact factor: 3.677

7.  Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.

Authors:  Kazuya Ishiguro; Yasushi Sasaki; Yoshitake Takagi; Takeshi Niinuma; Hiromu Suzuki; Takashi Tokino; Toshiaki Hayashi; Tohru Takahashi; Tetsuyuki Igarashi; Yoshihiro Matsuno
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.